Onco Actu du 4 mai 2016

	1.1 Biologie - Gènes
DNA analysis brings scientists step closer to ‘complete picture’ of breast cancer [Cancer Research UK] The studies, led by scientists at the Wellcome Trust Sanger Institute, analysed the complete genetic code – or genome – of 560 breast tumours. The analysis uncovered five genes newly associated with the disease.
	2.6 Etiologie - Environnement
Polluted air may up risk of many cancers [Reuters] “At an individual level the strongest risk factors for cancer are smoking and diet,” she said. “However, at a population level, given the wide distribution of exposure, even a small increase in risk can result in a large number of cases.”
	3.1 Tabac
EU's highest court upholds restrictive new law on cigarettes [Reuters Europe's highest court on Wednesday upheld a tough EU law that will standardize cigarette packs, ban menthol flavoring and restrict e-cigarette advertising, paving the way for its adoption this month and dealing a blow to Big Tobacco.
	4.5 Dép., diag. & prono. - Colorectal
Colonoscopies get the glory, but reasons for dramatic decline in colon cancer are unclear [HealthNewsReview] There’s nothing wrong with organizations wanting to advocate for more colon cancer screening awareness. But truly informing the public is different than mindlessly promoting a procedure.
	5.12 Immunothérapies
Global Cancer Immunotherapies Market 2016-2020 [ReportsnReports] The analysts forecast global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020.
	5.2 Pharma
FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma [Lilly] Olaratumab Previously Received Breakthrough Therapy Designation.
	5.2.2 Pharma - Fusions & Acquisitions
Pfizer considers a move on Medivation [PharmaTimes] Sanofi could be facing some tough competition in its quest for Medivation, as Pfizer has reportedly now also stepped forward to express an interest in acquiring the firm.
	5.2.3 Pharma - économie
Celgene, Novartis back $46M Series A in next oncology play from Flexus execs [FierceBiotech] The new company, dubbed Ideaya Biosciences, is focused on inducing synthetic lethality, the notion that the combination of two specific paired mutations can lead to cell death, as well as on immuno-oncology. The idea is to develop candidates for specific genetic populations and to combine the two approaches to enhance tumor response.
Biotech’s behind-the-scenes baroness redefined how universities launch startups [STAT] She ran one of the country’s largest and most successful technology transfer offices, an unglamorous yet essential go-between for universities and startups. And any time a venture capitalist, a pharmaceutical company, or a tech titan wanted to cash in on an invention at the Massachusetts Institute of Technology, each had to go through her.
The World’s Most Expensive Medicine Is a Bust [MIT Techonology Review] The most expensive drug in history is a money loser that’s not reaching patients. In fact, it’s only been paid for and used commercially once since being approved in 2012. The medication in question is alipogene tiparvovec, better known as Glybera, a medicine widely heralded as the “first gene therapy” in the Western world and whose approval helped ignite an explosion of investment and excitement around treatments that correct DNA.
Pfizer Guides Higher, Mulls Breakup of Company [Wall Street Journal] Among the products contributing to Pfizer’s growing sales are pneumonia vaccine Prevnar, breast-cancer drug Ibrance and blood-thinner Eliquis.
	5.3 Traitements - FDA, EMA,...
Genomic Data and Drug Development: EMA Offers New Draft Guidance [RAPS] EMA warns that some clinical studies on pharmacogenomics have resulted in “ambiguous findings,” which highlights the importance of correctly measuring, interpreting and translating pharmacogenomic data into clinical treatment.
What We Mean When We Talk About EvGen Part II: Building Out a National System for Evidence Generation [FDA Voice] In an earlier FDA Voice blog post, we discussed a pair of concepts – interoperability and connectivity – that are essential prerequisites for the creation of a successful national system for evidence generation (or “EvGen”). In this post, we take a look at how we would apply these constructs as we go about building such a system.
	6. Lutte contre les cancers
Set up a public registry of competing interests [Nature News & Comment] The problem of bias in published research must be tackled in a consistent and comprehensive fashion.
	6.7 DMP, Big Data & applis
Quintiles, IMS Health unveil surprise megamerger [FierceBiotech] The deal will, in essence, merge the real-world clinical applications of Quintiles’ business with IMS Health’s data gathering and analysis, as well as its access to patient, prescription and other key healthcare data, giving the new company a pool of information for drugmakers.
Quintiles and IMS Health announce plans to merge [PharmaTimes] The combined entity, which is to be called Quintiles IMS, will offer a distinctive global real-world evidence solutions platform underpinned by “a leading portfolio” of anonymous patient records, technology-enabled data collection and observational research experts, to help address critical healthcare issues of cost, value and patient outcomes.
Google given access to London patient records for research [BBC News] Under the data-sharing agreement, Google's artificial intelligence division DeepMind will have access to all of the data of patients from the Royal Free, Barnet and Chase Farm hospitals in London going back over the past five years and continuing until 2017.
	6.9 Controverses
The gene editor CRISPR won’t fully fix sick people anytime soon. Here’s why [Science] CRISPR also poses its own safety risks. Most often mentioned is that the Cas9 enzyme that CRISPR uses to cleave DNA at a specific location could also make cuts where it’s not intended to, potentially causing cancer.
Johnson & Johnson hit with $55m damages in talc cancer case [BBC News] The company - which faces about 1,200 similar claims - insists its products are safe and says it will appeal. Researchers say links with ovarian cancer are unproven.
Why can’t all illnesses get the cancer treatment? [The Guardian] I hope the latest breast cancer breakthrough is genuine. But I also wish we paid as much attention to other severe conditions.